Session

IBD (Posters)

REAL WORLD USE OF THE IBD DISK TOOL IN UNSELECTED COHORTS OF OUTPATIENTS
REAL WORLD USE OF THE IBD DISK TOOL IN UNSELECTED COHORTS OF OUTPATIENTS

IBD (Posters)  et al.

IDENTIFICATION OF CONSTITUTIVE MODIFICATIONS IN PLASMA CELLS AND B LYMPHOCYTES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
IDENTIFICATION OF CONSTITUTIVE MODIFICATIONS IN PLASMA CELLS AND B LYMPHOCYTES IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY
FECAL CALPROTECTIN AS A SURROGATE MARKER OF CLINICAL REMISSION, CLINICAL RESPONSE, ENDOSCOPIC IMPROVEMENT, AND HISTO-ENDOSCOPIC MUCOSAL HEALING: UNIFI INDUCTION STUDY

IBD (Posters)  et al.

IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID
IMPACT OF ABDOMINOPELVIC RADIOTHERAPY ON INFLAMMATORY BOWEL DISEASE ACTIVITY: A MULTICENTER COHORT STUDY FROM THE GETAID

IBD (Posters)  et al.

EVALUATION OF INTEREST AND KEY FEATURES OF A HEALTH CARE APP TO ASSIST IN THE MANAGEMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AMONGST CLINICAL TRIAL SITES IN THE UNITED STATES
EVALUATION OF INTEREST AND KEY FEATURES OF A HEALTH CARE APP TO ASSIST IN THE MANAGEMENT OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE AMONGST CLINICAL TRIAL SITES IN THE UNITED STATES

IBD (Posters)  et al.

GENETIC TESTING OF HLA-DQA1-HLA-DRB1 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
GENETIC TESTING OF HLA-DQA1-HLA-DRB1 IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

IBD (Posters)  et al.

SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY
SERUM CALPROTECTIN IS NOT EFFECTIVE TO PREDICT IBD RELAPSE AND HAS WEAK DIAGNOSIS ACCURACY

IBD (Posters)  et al.

NON-SUPPRESSIVE FOXP3+ T HELPER CELLS, BUT NOT REGULATORY T CELLS, ARE INCREASED IN COLLAGENOUS COLITIS MUCOSA
NON-SUPPRESSIVE FOXP3+ T HELPER CELLS, BUT NOT REGULATORY T CELLS, ARE INCREASED IN COLLAGENOUS COLITIS MUCOSA

IBD (Posters)  et al.

PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS
PRIMARY STUDY RESULTS FROM GO OBSERVE: A REAL-WORLD EUROPEAN PROSPECTIVE SINGLE-ARM OBSERVATIONAL COHORT STUDY OF PATIENT-REPORTED CONTINUOUS CLINICAL RESPONSE TO GOLIMUMAB IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS

IBD (Posters)  et al.

EFFICACY OF USTEKINUMAB AT THE END OF MAINTENANCE IN ULCERATIVE COLITIS PATIENTS RECEIVING 6 MG/ KG INDUCTION POSOLOGY. DATA FROM UNIFI TRIAL
EFFICACY OF USTEKINUMAB AT THE END OF MAINTENANCE IN ULCERATIVE COLITIS PATIENTS RECEIVING 6 MG/ KG INDUCTION POSOLOGY. DATA FROM UNIFI TRIAL

IBD (Posters)  et al.

DIFFUSION-WEIGHTED MAGNETIC RESONANCE ENTEROCOLONOGRAPHY AND CDEIS IN ASSESSING CROHN´S DISEASE ACTIVITY
DIFFUSION-WEIGHTED MAGNETIC RESONANCE ENTEROCOLONOGRAPHY AND CDEIS IN ASSESSING CROHN´S DISEASE ACTIVITY

IBD (Posters)  et al.

ULCERATIVE COLITIS: CHARACTERISTICS OF INTESTINAL MICROBIOTA IN RUSSIAN POPULATION
ULCERATIVE COLITIS: CHARACTERISTICS OF INTESTINAL MICROBIOTA IN RUSSIAN POPULATION

IBD (Posters)  et al.

TRANSCRIPTIONAL CHANGES AFTER BUDESONIDE TREATMENT IN COLLAGENOUS COLITIS PATIENTS
TRANSCRIPTIONAL CHANGES AFTER BUDESONIDE TREATMENT IN COLLAGENOUS COLITIS PATIENTS

IBD (Posters)  et al.

METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS
METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS

IBD (Posters)  et al.

RESPONSE TO INDUCTION TREATMENT WITH BIOLOGICALS IN A MULTICENTER, PROSPECTIVE COHORT OF BIOLOGICAL-NAïVE IBD PATIENTS - PRELIMINARY RESULTS FROM THE DANISH IBD BIOBANK PROJECT
RESPONSE TO INDUCTION TREATMENT WITH BIOLOGICALS IN A MULTICENTER, PROSPECTIVE COHORT OF BIOLOGICAL-NAïVE IBD PATIENTS - PRELIMINARY RESULTS FROM THE DANISH IBD BIOBANK PROJECT

IBD (Posters)  et al.

TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT
TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT

IBD (Posters)  et al.

COMPARATIVE BIOAVAILABILITY OF NOVEL CYCLOSPORINE FORMULATIONS VERSUS REFERENCE ORAL CYCLOSPORINE IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS
COMPARATIVE BIOAVAILABILITY OF NOVEL CYCLOSPORINE FORMULATIONS VERSUS REFERENCE ORAL CYCLOSPORINE IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS

IBD (Posters)  et al.

MESALAZINE INDUCES EARLY HISTO-ENDOSCOPIC MUCOSAL HEALING IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POST-HOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS
MESALAZINE INDUCES EARLY HISTO-ENDOSCOPIC MUCOSAL HEALING IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POST-HOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS

IBD (Posters)  et al.

VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE
VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE

IBD (Posters)  et al.

INTEGRATION OF EHEALTH FOR PAEDIATRIC IBD IN REAL LIFE IS SAFE
INTEGRATION OF EHEALTH FOR PAEDIATRIC IBD IN REAL LIFE IS SAFE

IBD (Posters)  et al.

Item 321 - 340 / 558
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
17
18 19 20 21 22 23 24 25 26 27 28